Home > Pulmonology > NLC 2022 > Challenges in Upper Airway Diseases > The role of biologics in CRSwNP

The role of biologics in CRSwNP

Presented By
Prof. Lars-Olaf Cardell, Karolinska Institute, Sweden
Conference
NLC 2022
Doi
https://doi.org/10.55788/cb283d91
Currently, 4 biologics targeting type2 inflammatory mechanisms have been approved for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and available in many Western countries, i.e. omalizumab, mepolizumab, benralizumab, and dupilumab. Their future positioning and use as non-surgical treatment for CRSwNP will heavily rely on their cost-effectiveness. “For a more accurate assessment of cost-effectiveness, both direct and indirect costs should be included in health-economic evaluations (including risks and side effects of current treatment options: corticosteroids and surgery) as well as concurrently treated comorbidities (e.g. asthma),” Prof. Lars-Olaf Cardell (Karolinska Institute, Sweden) explained. A review by Patel et al., which involved omalizumab (n=12), mepolizumab (n=42), benralizumab (n=44), reslizumab (n=6), and dupilumab (n=61), demonstrated that type2–targeting biologics can reduce the use of medication (corticosteroids/antibiot...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on